Vanguard Amends 13G/A: Reports 0 Shares in Altimmune
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting its position in Altimmune Inc. The filing states 0 shares beneficially owned and 0% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting its position in Altimmune Inc. The filing states 0 shares beneficially owned and 0% of the class. The amendment explains an internal realignment and separate reporting by Vanguard subsidiaries in accordance with SEC Release No. 34-39538.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Vanguard file Amendment No. 3 for Altimmune (ALT)?
Who signed the Altimmune (ALT) Schedule 13G/A amendment for Vanguard?
What address is listed for Altimmune in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.